BMGL vs. TOI, AIRS, DCGO, EUDA, CORBF, XGN, ATPC, SERA, KDLY, and QIPT
Should you be buying Basel Medical Group stock or one of its competitors? The main competitors of Basel Medical Group include Oncology Institute (TOI), AirSculpt Technologies (AIRS), DocGo (DCGO), EUDA Health (EUDA), Global Cord Blood (CORBF), Exagen (XGN), Agape ATP (ATPC), Sera Prognostics (SERA), Kindly MD (KDLY), and Quipt Home Medical (QIPT). These companies are all part of the "healthcare" industry.
Basel Medical Group vs.
Basel Medical Group (NASDAQ:BMGL) and Oncology Institute (NASDAQ:TOI) are both small-cap services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.
36.9% of Oncology Institute shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Oncology Institute had 2 more articles in the media than Basel Medical Group. MarketBeat recorded 5 mentions for Oncology Institute and 3 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.95 beat Oncology Institute's score of 0.13 indicating that Basel Medical Group is being referred to more favorably in the media.
Oncology Institute has a consensus target price of $7.00, suggesting a potential upside of 133.10%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts plainly believe Oncology Institute is more favorable than Basel Medical Group.
Basel Medical Group has a net margin of 0.00% compared to Oncology Institute's net margin of -17.63%. Basel Medical Group's return on equity of 0.00% beat Oncology Institute's return on equity.
Basel Medical Group has higher earnings, but lower revenue than Oncology Institute.
Oncology Institute received 5 more outperform votes than Basel Medical Group when rated by MarketBeat users.
Summary
Oncology Institute beats Basel Medical Group on 8 of the 13 factors compared between the two stocks.
Get Basel Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Basel Medical Group Competitors List
Related Companies and Tools
This page (NASDAQ:BMGL) was last updated on 5/23/2025 by MarketBeat.com Staff